Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., incorporated on December 06, 2012, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing a pipeline of product and development candidates, with a focus on serious fungal infections. The Company's lead clinical candidates are echinocandins, a class of antifungals. The Company's product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. In addition, it has developed an immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. It is evaluating Cloudbreak candidates for the treatment of invasive fungal infections, including aspergillosis, an infection caused by the fungal pathogen, Aspergillus. The Company is also developing CD201, its bispecific antimicrobial immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections.
CD101 IV
The Company's CD101 IV is a molecule in the echinocandin class of antifungals. The Company is developing CD101 IV for the treatment of systemic Candida infections. These infections include candidemia and related cases of invasive candidiasis, which are fungal infections associated with high mortality rates. The treatment alternatives for systemic fungal infections, including polyenes, azoles and echinocandins, have limitations that may be addressed by antifungals. CD101 IV has a prolonged half-life, which in contrast to all other echinocandins, may allow for once-weekly intravenous (IV) therapy.
CD101 Topical
The Company is developing CD101 topical, a topical formulation of CD101, for the treatment of VVC and RVVC. The active ingredient in CD101 topical is CD101, which has demonstrated potent fungicidal activity against Candida species in preclinical studies. The fungicidal activity of CD101 at the site of infection has the potential to be more effective than the fungistatic azoles in reducing recurrence of Candida infections in women with RVVC. CD101 can be formulated topically due to its high solubility, stability and activity over a range of potential of Hydrogen (pH) values.
Cloudbreak Immunotherapy Platform
The Company's Cloudbreak candidates are designed to address the deficiency by recruiting components of the patient's immune system to the site of infection, enabling effective treatment. The initial candidates emerging from the Cloudbreak immunotherapy platform are being developed for the treatment of invasive aspergillosis, a fungal infection that results in a high rate of mortality. The modular composition of Cloudbreak compounds allows for rapid exploration of combinations of targeting moiety (TM), effector moiety (EM), and linker domains, enabling efficient discovery of anti-infective molecules with the desired potency, specificity and physical properties.
CD201
CD201 is the first development candidate from the Company?ÇÖs Cloudbreak immunotherapy discovery platform. CD201 works by binding to a target present on a range of Gram-negative bacteria, including MCR-1-positive strains. CD201 has demonstrated preliminary efficacy and safety in a number of animal models of infection.
The Company competes with Merck & Co., Pfizer, Inc., Astellas Pharma US, Inc., Baxter Healthcare Corporation, Mylan Inc., Glenmark Generics Inc., Gilead Sciences, Inc., Basilea Pharmaceutica Ltd., Novartis and Teva Pharmaceutical Industries Ltd.
6310 Nancy Ridge Dr Ste 101
The company trades on NASDAQ exchange. The company headquarter is located in California, CA. The company was established in the 2012.| Ticker | CDTX |
| Long Name | Cidara Therapeutics, Inc. |
| Short Name | Cidara Therapeutics |